Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Monday, January 11, 2016 9:30 AM

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

In the phase II LUX-Breast 3 trial reported in The Lancet Oncology, Cortés et al found that afatinib (Gilotrif) alone or combined with vinorelbine did not increase patient benefit vs investigator choice of treatment in patients with HER2-positive breast cancer and progressive brain...

breast cancer

By Caroline Helwick / Monday, September 29, 2014 11:38 AM

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...

Jul

Today In Oncology

Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

COVID-19 Boosters Offer Protection for Patients With Cancer

Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes

Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates

Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer

Classifying Pancreatic Cysts Using AI Models